This proposal seeks a renewal of funding for the United States based International Breast Cancer Study Group (IBCSG) Statistical and Data Management Center, a resource that contributes to International -US collaboration in the following areas: Access to the IBCSG clinical database of 22,475 breast cancer patients enrolled in large-scale, randomized clinical trials with up to 26 years maximum follow-up; Access to the IBCSG tissue bank database for over 2000 patients with 10-20 years median follow-up; Expertise of statistical and medical investigators and collaboration in the IBCSG research agenda. This resource gives NCI an opportunity to significantly improve our understanding of treatment and prognosis of women with operable breast cancer. Participation of the IBCSG in US trials and enrollment of US patients in IBCSG trials, are essential to accrue the large number of patients needed to make real progress, especially in trials assessing treatments in relatively rare patient populations (e.g., very young women). As our understanding of the pathogenesis of breast cancer and targeted treatment responsiveness increases, the need for tailored treatment investigations focusing on more homogeneous patient cohorts also increases. Support of this proposal to continue the successful IBCSG-NCI partnership will result in enhancing the effective use of improved endocrine therapies, defining the role of chemotherapy for older and younger women, assessing maintenance metronomic chemotherapy following standard cytotoxic treatment, and evaluating chemotherapy after loco-regional recurrence. The long range goal of the IBCSG is to determine the best possible treatments for operable breast cancer.
The specific aims of this application comprise the major areas of research toward this goal: To provide US-based statistical and data management collaboration for the design, conduct, analysis, and reporting of IBCSG randomized clinical trials evaluating adjuvant therapies; To facilitate correlative research by providing access to out uniformly treated and followed populations of patients with tissue collection at diagnosis; To facilitate collaboration on database studies to identify and confirm the relationship between characteristics of breast cancer patients and/or tumors and response to adjuvant therapies; To enhance collaboration between the IBCSG and US cooperative groups in the area of quality-of-life evaluation for patients with breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA075362-10
Application #
7255528
Study Section
Subcommittee G - Education (NCI)
Program Officer
Zujewski, Jo Anne
Project Start
1997-09-30
Project End
2010-12-31
Budget Start
2007-01-01
Budget End
2007-12-31
Support Year
10
Fiscal Year
2007
Total Cost
$459,529
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Wapnir, Irene L; Price, Karen N; Anderson, Stewart J et al. (2018) Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol 36:1073-1079
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Lazar, Ann A; Bonetti, Marco; Cole, Bernard F et al. (2016) Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP. Clin Trials 13:169-79
Wolmark, Norman; Mamounas, Eleftherios P; Baehner, Frederick L et al. (2016) Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/Nati J Clin Oncol 34:2350-8
Yip, Wai-Ki; Bonetti, Marco; Cole, Bernard F et al. (2016) Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes. Clin Trials 13:382-90
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Bellet, Meritxell; Gray, Kathryn P; Francis, Prudence A et al. (2016) Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol 34:1584-93

Showing the most recent 10 out of 71 publications